Scribe Therapeutics will participate in SVB Securities Biopharma Private Company Connect



ALAMEDA, Calif.–(BUSINESS WIRE)–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the virtual Biopharma Private Company Connect event hosted by SVB Securities on July 20-21, 2022. , whose CEO and co-founder Benjamin Oakes, PhD, and CFO David Parrot, will hold one-on-one virtual meetings with investors during the event. Meetings with the management team can be requested through SVB Securities.

About Scribe Therapeutics

Scribe Therapeutics is a molecular engineering company focused on creating cutting-edge in vivo therapies that permanently address the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage and Jennifer Doudna, Scribe overcomes the limitations of current genome editing technologies by developing personalized enzymes and delivery modalities within the framework of a proprietary and scalable platform for CRISPR-based genetic medicine. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., managed funds by Wellington Management, RA Capital Management, and Menlo Ventures. To learn more about Scribe’s mission to shape the future of genetic medicine, visit

Source link


Comments are closed.